See Cyxone’s presentation below.
BioStock Investor Meeting: Cyxone presents
Carl-Magnus Högerkorp recently assumed the role as acting CEO of Cyxone. The biopharmaceutical company is currently awaiting approval of the phase II study with the candidate Rabeximod in rheumatoid arthritis. At the BioStock Investor Meeting in Stockholm, Högerkorp talked about the preparations for the start of the study and what lies ahead for the company.
Notiser
Nosa Plugs expanderar till Norge
BrainCool pausar stroke-studie
PHI får ny vd
AcouSort utökar europeiskt samarbete
Integrum stärker distribution i Ukraina
NYHETSBREV
NYHETER
Lovande preliminära resultat för Elicera Therapeutics CAR T-cellstudie
Active Biotech stiger på lovande data
Cereno Scientific går framåt på bred front under Q1
Kommande event!
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region’s leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
Du är värd det bästa!
Lås upp vårt premium-innehåll: Bli prenumerant!
Skapa konto
Krönikor
Fruergaard Jørgensen lämnar – något är på tok
Första draget gjort – nu väntar vi på svar
